X4 Pharmaceuticals Inc (NASDAQ:XFOR) Stock Is Shorted Less

The stock of X4 Pharmaceuticals Inc (NASDAQ:XFOR) registered a decrease of 3.45% in short interest. XFOR’s total short interest was 162,400 shares in August as published by FINRA. Its down 3.45% from 168,200 shares, reported previously. With 59,300 shares average volume, it will take short sellers 3 days to cover their XFOR’s short positions. The short interest to X4 Pharmaceuticals Inc’s float is 10.9%.

The stock increased 0.42% or $0.05 during the last trading session, reaching $12.05. About 9,614 shares traded. X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has declined 18.72% since August 13, 2018 and is downtrending. It has underperformed by 18.72% the S&P500.

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. The company has market cap of $149.67 million. The Company’s lead drug candidate is mavorixafor , an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It currently has negative earnings. The firm is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies.

More notable recent X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) news were published by: Businesswire.com which released: “Senior Housing Properties Trust Announces Second Quarter 2019 Results – Business Wire” on August 08, 2019, also Seekingalpha.com with their article: “X4 Pharma launches equity offering – Seeking Alpha” published on April 11, 2019, Globenewswire.com published: “Tribune Publishing Reports Second Quarter 2019 Results Nasdaq:TPCO – GlobeNewswire” on August 07, 2019. More interesting news about X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) were released by: Nasdaq.com and their article: “Near-Term Prospects for Foreign Bank Stocks Appear Gloomy – Nasdaq” published on July 17, 2019 as well as Seekingalpha.com‘s news article titled: “Midatech Pharma leads healthcare gainers; TrovaGene and Cleveland BioLabs among losers – Seeking Alpha” with publication date: April 24, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.